Expression and clinical significance of PAK1 and BRAF V600E mutation in papillary thyroid carcinoma
10.3760/cma.j.issn.1007-631X.2016.06.015
- VernacularTitle:PAK1蛋白和BRAF V600E突变蛋白在甲状腺乳头状癌中的表达及其临床意义
- Author:
Qiang CHEN
;
Qingji XIE
;
Hong CEN
;
Cong TANG
- Publication Type:Journal Article
- Keywords:
Thyroid neoplasms;
Carcinoma,papillary
- From:
Chinese Journal of General Surgery
2016;31(6):486-489
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression of P-21 activated kinase 1 (PAK1) and v-raf murine sarcoma viral oncogene homolog B (BRAF) V600E mutation in papillary thyroid carcinoma (PTC)and their relationship with clinicopathological characteristics.Methods Immunohistochemistry was used to detect the expression of BRAF V600E mutation and P-21 activated kinase 1 (PAK1) in 55 PTC tissues and 25 benign thyroid tissues.The correlation between their expression and clinicopathological characteristics were analyzed.Results BRAF V600E mutation and PAK1 expressed differently between PTC and benign thyroid (respectively,x2 =12.121,9.950,all P ＜ 0.01).The expression of PAK1 and BRAF V600E mutation was positively and significantly correlated with tumor invasion,grades and lymph node metastasis(P ＜ 0.05),but it had no correlation with age,gender,tumor size,multiple tumor foci and bilateral tumor foci in PTC (P ＞ 0.05).Expression of PAK1 in BRAF V600E negative PTC was higher than that in BRAF V600E positive PTC,and expression of PAK1 and BRAF V600E mutation in PTC were negatively correlated(r =-0.284,P ＜ 0.05).Conclusion Overexpression of either BRAF V600E mutation or PAK1 predicts poor prognosis of PTC patients.
